Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
About
About the Journal
Editorial board
The Publisher
Abstracting and indexing
Publication ethics
Privacy Statement
Contact
Policies
Open access policy
Editorial policies
Authors' self archiving and sharing policy
Commercial policies
Privacy policy
Guidelines
Guidelines for authors
Guidelines for Reviewers
Artwork guidelines
Publication fees
Archives
Current
Search
Register
Login
Submit now
Home
/
Archives
/
Vol. 5 No. 1 (2018): January-December 2018
Vol. 5 No. 1 (2018): January-December 2018
DOI:
https://doi.org/10.1177/2284240318807726
Published:
2018-12-31
Original Research Articles
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group
Francesco S. Mennini, Raffaella Viti, Chiara Bini, Andrea Marcellusi, Fabio Palazzo
PDF
Burden of disease, healthcare pathways and costs of cardiovascular high-risk patients with type 2 diabetes: a real world analysis
L’onere della malattia, risorse sanitarie e costi dei pazienti con diabete di tipo 2 ad elevato rischio cardiovascolare: un’analisi “real world”
Carlo Piccinni, Letizia Dondi, Giulia Ronconi, Antonella Pedrini, Nello Martini, Giulio Marchesini
PDF
Assessing social and economic impact of subcutaneous mAbs in oncology
Americo Cicchetti, Silvia Coretti, Daniele Mascia, Nicola Mazzanti, Pietro Refolo, Francesca R. Rolli, Filippo Rumi1
PDF
A comparative examination of healthcare use related to hearing impairment in Europe
Mimi Xiao, Ciaran O’Neill
PDF
Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia
Elena P. Lanati, Paola La Malfa, Arianna Iorio, Francesco S. Mennini, Francesca Fanelli, Sandro Gentile
PDF
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto
Mennini FS, Pisanti P, Terzoni S, Lanati EP, Marcellusi A, Marcelli A, Iorio A
PDF
Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
Roberto Ravasio, Giampiero Girolomoni, Roberto Gorla
PDF
Patients’ Associations and HTA for medicines: actual and future role in Italy
Claudio Jommi, MSc, Arianna Bertolani, Phd
PDF
The economic impact of the correct insulin injection technique associated with the use of 4 mm 32G needles in the treatment of patients with type 2 diabetes
Roberto Ravasio, Giorgio Grassi
PDF
The hospitalization burden of influenza: just the tip of the iceberg?
Arianna Bertolani, Giovanni Fattore, Fabrizio Pregliasco
PDF
Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy
Sanja Stanisic, Alessia Marocco, Anna Gallo, Paolo Rama, Marta Sacchetti, Maurizio Rolando, Augusto Pocobelli, Roberto Ceccuzzi, Andrea Leonardi, Rita Mencucci, Emilio Pedrotti, Elisa Postorino, Maurizio Mascia, Lucia R Mazzamuto, Luisanna Prisco, Floortje Van Nooten, Patrizia Berto
PDF
Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective
Alessia Marocco, Sanja Stanisic, Francesca Fanelli, Francesco Damele, Furio Colivicchi
PDF
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
Carla Rognoni, Arianna Bertolani, Claudio Jommi
PDF
Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study
Carlo Lazzaro, Fabiano Di Marco, Nicola Scichilone, Fulvio Braido, Marco Contoli, Paola Rogliani, Pierachille Santus, Valentina Acciai, Carla Scognamillo, Irene Olivi, Angelo Guido Corsico
PDF
Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia
Sanja Stanisic, Americo Cicchetti, Camillo Porta, Giuseppe Procopio, Patrizia Berto
PDF
Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy
Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron, Serena Losi
PDF
Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA
Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini
PDF
Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco
Dario Lidonnici, Virginia Ronco, Martina Isernia, Elena Lanati, Claudio Jommi, Pier Luigi Canonico, Armando A. Genazzani
PDF
I costi dei pazienti con patologie infiammatorie dell’intestino (Malattia di Crohn e colite ulcerosa). Studio real world in Italia
Stefano Capri, Antonio Russo
PDF
Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia
Albrecht M, Nica M, Colombo D, Ferri C, Tadini P, Introini U, Bandello F
PDF
Evaluación del impacto presupuestario del servicio integral de asistencia domiciliaria nutricional
Javier Nuñez Alfonsel, Benedetto Ielpo, Villareal García-Lomas M, Cristóbal Belda Iniesta
PDF
Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study
Andrea Aiello, Daniela Ritrovato, Claudia Pitotti
PDF
A budget impact analysis of a clinical medication review of patients in an Irish university teaching hospital
Alan Kearney, Elaine K Walsh, Ann Kirby, Ciaran Halleran, Derina Byrne, Jennifer Haugh, Laura J Sahm
PDF
Erratum
Corrigendum
PDF
Sign up
Browse
Categories
Health Technology Assessment
Health Policies
banners150
Completed peer reviews since:
November 4, 2020